Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Designed to address emerging areas of patient need, including long-term weight management, co-morbid metabolic disorders, and muscle preservation during weight loss
Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. ('Nxera'; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders.
Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline across a broad range of validated GPCR targets in these major disorders.
Chris Cargill, President and CEO of Nxera, commented: 'Nxera scientists were among the pioneers in elucidating the structure of the GLP-1 receptor and other key receptors being targeted, giving us a clear advantage in developing potentially best-in-class next generation drug candidates. For the past 12 months, Nxera scientists have been advancing a broad metabolic disease pipeline to capitalize independently on our differentiated science. Today, we reveal the addition of these programs to our discovery portfolio, and are confident in achieving significant progress over the mid-term, delivering clear value for shareholders and patients in the rapidly expanding obesity market, projected to exceed US$100 billion annually in global sales.'
Central to Nxera's pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from Pfizer's PF-06954522, allowing Nxera full control to drive rapid progress.
Complementing this program, Nxera is simultaneously accelerating the advancement of an additional six established GPCR-targeted programs focused on obesity and chronic weight management:
Three small molecule agonist programs (GIP, Apelin, Amylin)
One small molecule antagonist program (GIP)
Two long-acting programs (targets undisclosed)
Nxera's pipeline leverages its proprietary NxWave™ GPCR-focused structure-based design platform to rapidly identify unique, highly differentiated lead molecules with novel chemistry. This process utilizes Nxera's NxHit proprietary small molecule libraries and NxStaR proteins for DNA encoded library (DEL) screening, distinguishing these candidates from others currently in discovery and clinical development globally.
Nxera's focused approach is designed to deliver highly effective therapies addressing critical patient needs:
Long-term weight maintenance: Convenient, scalable oral therapies for sustained weight loss.
Targeting key obesity-related co-morbidities: Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously.
Reducing side effects and broadening out to difficult to treat populations: Targeted treatments for elderly, post-menopausal, and sarcopenic populations.
Backed by an expert team with deep experience in GPCR drug discovery, Nxera is strategically positioned to be a leader in developing the next generation of best-in-class obesity and metabolic therapies.
Nxera maintains its strong commitment to other key therapeutic areas including neurology, gastroenterology, and immunology, continuing to leverage the NxWave™ platform's proven capabilities in these domains.
Separately, Nxera notes that Pfizer yesterday discontinued development of its Phase 1 candidate PF-06954522, a separate small molecule GLP-1 agonist, which was discovered under a strategic drug discovery collaboration with Nxera. This discontinuation by Pfizer was due to a portfolio decision and not because of any adverse safety findings. Nxera intends to enter discussions with Pfizer regarding potential opportunities to advance GLP-1 molecules discovered by Pfizer under the collaboration.
Nxera will announce its earnings results and present operational highlights for Q2 2025 on Friday, 8 August 2025.
–END–
About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.
We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region.
Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation.
Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
For more information, please visit www.nxera.life LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma
Enquiries:
Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@Nxera.life
MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@medistrava.com
Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
39 minutes ago
- Business Wire
Prefer Launches Soluble Coffee and Cocoa Powders for the food industry, Raises Oversubscribed US$4.2M Pre-A to Fuel International Expansion
SINGAPORE--(BUSINESS WIRE)--Prefer, a Singapore-based food tech startup using fermentation to create affordable and sustainable flavours and ingredients, today announced an oversubscribed US$4.2 million fundraising round alongside the commercial launch of its new products: soluble coffee and cocoa powders. The company also announced its first commercial partnerships for international expansion with Ajinomoto Co., (Thailand) Ltd and The Coffee Ferm in Thailand and Australia, respectively. 'With the support of our new partners, the quality of our new products, and the grit of this team, we're in a unique position to ensure coffee and cocoa are accessible to the masses while respecting our planet,' says Jake Berber, Co-Founder & CEO Share Made from food manufacturing byproducts such as rice and soy, Prefer's flavours are developed using a proprietary fermentation and roasting process. The company supplies its flavours and ingredients to FMCG brands, food manufacturers, private label retailers, and flavour houses, offering affordable ingredients that replicate the taste and functionality of coffee and cocoa at a fraction of the carbon footprint. According to its life cycle analysis, Prefer's coffee has up to 85% lower emissions and is 50% more affordable than the current market prices of traditional Arabica. Prefer invites coffee and cocoa companies to connect and sample the ingredients via their website, offering partners a commercially proven ingredient that drives cost savings, strengthens supply chain resilience, and supports the planet. 'With the support of our new partners, the quality of our new products, and the grit of this team, we're in a unique position to ensure coffee and cocoa are accessible to the masses while respecting our planet,' says Jake Berber, Co-Founder & CEO. This funding round brings Prefer's total equity raised to US$6.2 million. The lead investors are At One Ventures and Chancery Hill Capital, with participation from existing investor, Forge Ventures. 'We're in the early stages of a food system transformation, one that decouples beloved consumer products from environmentally harmful supply chains,' says Helen Lin, Partner at At One Ventures and board member at Prefer. The startup recently commercialised its coffee products through foodservice channels, collaborating with Melvados, a Singaporean food business. The company also announced its first international commercial partnerships. In Thailand, Prefer is working with Ajinomoto Co., (Thailand) Ltd. to develop sustainable new innovations under coffee beverage aligned with the 'Eat Well, Live Well' lifestyle. In Australia and New Zealand, the company has partnered with The Coffee Ferm, which will license Prefer's flavour IP to scale local manufacturing and distribution. Prefer plans to scale its pilot production facility through toll manufacturers in key markets, deepen R&D on cocoa flavour development, and expand global partnerships with a continued focus in Asia. About Prefer Founded in 2022 by Jake Berber and Ding Jie Tan, Prefer is a Singapore-based food tech company using fermentation to create affordable and sustainable flavours and ingredients. Starting with coffee and cocoa, Prefer transforms upcycled ingredients into climate-resilient alternatives for the food industry. Media Kit
CNBC
4 hours ago
- CNBC
FDA may pull authorization of Pfizer's Covid vaccine for children under 5, company says
Key Points The Food and Drug Administration is considering revoking its authorization of Pfizer's Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC. The move could leave many kids with no available shots against the virus, though Moderna's shot will be an option for those at increased risk of severe illness due to at least one underlying condition. It would add to a string of recent efforts by U.S. health agencies to change and undermine immunization policy since Health and Human Services Secretary Robert F. Kennedy Jr., a prominent vaccine skeptic, took the helm. In this article PFE Follow your favorite stocksCREATE FREE ACCOUNT A nurse prepares doses of the Pfizer vaccine during a COVID-19 vaccination event at Josephine's Southern Cooking in Chatham, Illinois, Dec. 30, 2021. Brian Cassella | Tribune News Service | Getty Images The Food and Drug Administration is considering revoking its authorization of Pfizer 's Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC on Tuesday. The move could leave many kids with no available shot against the virus, as jabs from Moderna and Novavax are cleared for more limited populations. While Covid typically causes mild symptoms in most children, others, such as infants under 1 or those with certain health conditions, can be at a higher risk of severe illness and hospitalization. If the FDA pulls the authorization, it would add to a string of recent efforts by U.S. health agencies to change and undermine immunization policy since Health and Human Services Secretary Robert F. Kennedy Jr., a prominent vaccine skeptic, took the helm. HHS did not immediately respond to a request for comment. The FDA told Pfizer it might not renew its longstanding emergency use authorization for children ages 6 months to 4 years, the company said in a statement. Pfizer said it has requested the authorization to remain in place for the upcoming fall and winter season and is "currently in discussions with the agency on potential paths forward." The company said that the FDA's "deliberations" are not related to the safety and efficacy of the shot, "which continues to demonstrate a favorable profile." The Guardian first reported on the FDA's potential move. Moderna is working with the Centers for Disease Control and Prevention to boost supplies of its own Covid shot for children, the Guardian reported Saturday. In July, the FDA granted full approval to Moderna's Covid vaccine for children — but only for those with one more more health conditions that may put them at increased risk of severe illness if they become infected. The shots from both Moderna and Pfizer use messenger RNA technology. Kennedy has targeted those vaccines in the past, filing a petition in May 2021 demanding that the agency revoke authorization of the jabs. Meanwhile, Novavax 's protein-based shot has never been available for children under 12. In May, Kennedy announced that the Centers for Disease Control and Prevention has removed its recommendation of Covid vaccines for healthy children and pregnant women. But in updated guidance days later, the CDC said the shots "may" be given to those kids if a doctor agreed that it was necessary. Covid vaccines during pregnancy are now listed as "No Guidance/Not Applicable," where they were previously recommended for all pregnant adults.
Indianapolis Star
6 hours ago
- Indianapolis Star
Texas AG sues Eli Lilly for allegedly bribing medical providers to prescribe Lilly drugs
Texas Attorney General Ken Paxton is suing Eli Lilly, alleging the Indianapolis pharmaceutical company offered kickbacks to medical providers in exchange for prescribing more than a dozen of the company's drugs, including blockbuster GLP-1 weight loss drugs Mounjaro and Zepbound. Eli Lilly offered illegal incentives to Texas medical providers, including a "free nurse" program and reimbursement support services, to steer providers to provide the company's drugs, Paxton alleges in a lawsuit filed August 11 in a Texas district court. Lilly, one of the world's largest pharmaceutical companies, denied the allegations in an August 12 statement to IndyStar. The Lilly programs mentioned in the suit offered free trainings for nurses and medical providers, which helped Lilly market their drugs when they launched, the suit says. According to Paxton's office, many Texas residents prescribed these drugs were on state Medicaid, so these actions violated the Texas Health Care Program Fraud Prevention Act. 'Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme,' Paxton said in a news release. 'Eli Lilly fraudulently sought to maximize profits at taxpayer expense and put corporate greed over people's health. I will not stand by while corporations unlawfully manipulate our healthcare system to line their own pockets.' A spokesperson for Eli Lilly said the company denies the allegations and plans to defend against them in court. It's not the first time Paxton has taken a stab at Lilly in the courts. In October, Paxton sued insulin manufacturers and pharmacy benefit managers, including Lilly, Express Scripts and CVS, for allegedly concocting a conspiracy to increase insulin prices. Health Choice Alliance LLC, a New Jersey based company, joined Texas as a plaintiff. Health Choice has sued Lilly in the past, alleging the company engages in kickbacks. 'Multiple courts and the federal government have rejected claims by this same corporate relator against Lilly as meritless," a Lilly spokesperson said in a statement. "In fact, the United States government determined that 'the relators' allegations lack sufficient factual and legal support' in a prior case, explaining that 'federal healthcare programs have a strong interest in ensuring that, after a physician has appropriately prescribed a medication, patients have access to basic product support relating to their medication.' We intend to vigorously defend against these allegations.' At the heart of the Texas lawsuit is a class of drugs named GLP-1s prescribed for diabetes and weight loss. Named for the gut hormone receptor the drug targets, injectable GLP-1s have exploded in popularity since Zepbound hit the market in late 2023. Weight loss drugs: Eli Lilly closer to breakthrough weight loss drug; shares tumble as some question results The kickback lawsuit against Lilly is one way Paxton is protecting Texas patients "from corporate schemes that undermine the integrity of the healthcare system," according to his office.
